Sangamo Biosciences, Inc. (SGMO) Posts Q2 EPS Loss of $0.20, Releases FY11 Sales Guidance
Tweet
Share
E-mailGet Alerts SGMO Hot Sheet
Join SI Premium – FREE
Sangamo Biosciences, Inc. (NASDAQ: SGMO) reported Q2 EPS of ($0.20), $0.04 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $2.65 million.
Sangamo Biosciences, Inc. sees FY2011 revenue of $10-$12 million, versus the consensus of $11.03 million.
Sangamo Biosciences, Inc. sees FY2011 revenue of $10-$12 million, versus the consensus of $11.03 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
- Brinker sets revenue and unit growth targets through fiscal 2029
- Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss of $0.75/sh
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
